<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B7649F1A-A5EF-42F9-AF45-B29CD6EEC56C"><gtr:id>B7649F1A-A5EF-42F9-AF45-B29CD6EEC56C</gtr:id><gtr:firstName>Vincenzo</gtr:firstName><gtr:surname>D'Angiolella</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_12007"><gtr:id>603F173C-A9D9-41E8-AE7A-690B21C1FC17</gtr:id><gtr:title>important discovery, in collaboration with the Bartek and Halazonites labs, that the cyclin E oncogene, amongst others, produces replication stress required for ATM activation of senescence (Bartkova et al, Nature 2006: this paper is amongst the top</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_12007</gtr:grantReference><gtr:abstractText>In each cell division cycle, cells replicate their DNA (in S-phase) and distribute the genetic information equally to the daughter cells (in M-phase). Cell cycle phase transitions are processed in a very accurate and ordered manner, and these transitions can be blocked by multiple checkpoint mechanisms that monitor each phase for completion and fidelity. During cell cycle transitions and checkpoints, rapid elimination of proteins is controlled by ubiquitin-mediated proteolysis. Cells will tag a protein by attaching a ubiquitin molecule, and the proteasome complex searches out and destroys ubiquitin-tagged proteins, like a garbage truck collecting trash. 

The orchestrated action of protein degradation and synthesis ensures the correct execution of each cell cycle phase and coordinates the proper response to exogenous stimuli such as genotoxic stress. Alteration of the mechanisms monitoring cell cycle progression leads to cancer whereby cell proliferation is not integrated with checkpoint control signals. Instead cancer cells tend to proliferate in an uncontrolled fashion and become insensitive to the checkpoint signaling that ensures accurate replication of DNA. 

Further investigation of the basic regulatory machinery responsible for catalyzing cell cycle progression and ubiquitin-mediated proteolysis will uncover novel targets for growth inhibition to attack cancer cells.</gtr:abstractText><gtr:technicalSummary>Each cell in our body undergoes repetitive cycles of cell division characterized by DNA replication during S-phase, and DNA distribution to the daughter cells in M-phase. Essential for the replication of DNA are the constitutive building blocks of deoxyribonucleotides (dNTPs), which are produced by Ribonucleotide Reductase (RNR). RNR catalyzes the conversion of ribonucleotides (NTPs) to deoxyribonucleotides (dNTPs) for the synthesis of DNA during DNA replication and DNA repair. In human cells the catalytic site of RNR is formed when two RRM2 subunits are bound to two Ribonucleotide Reductase family Member 1 (RRM1) subunits. The RRM1 subunit is constantly expressed through the cell cycle. RRM2 subunit is only present during S-phase and regulated at the transcriptional and post-translational levels. We have observed that RRM2 protein is targeted by the ubiquitin proteasome system during G2-phase and M-phase of the cell cycle (D?Angiolella et al., Cell 2012). RRM2 is targeted for proteolysis by the SCFCyclin F ubiquitin ligase. Cyclin F (also known as Fbxo1) is the founding member of the E3 ligases F-box protein family and is essential for mouse development. 
The ubiquitin-mediated proteolysis of RRM2 by Cyclin F is required to maintain balanced levels of dNTPs during cell cycle progression. Failure to regulate dNTP levels properly causes a hyper-mutator phenotype. 
After genotoxic stress, RRM2 levels increase and Cyclin F is itself degraded through the activation of ATR. Such regulation allows cells to produce dNTPs for DNA repair. Accordingly, we observed that Cyclin F overexpression sensitizes cells to Ionizing Radiation (IR). Therefore, proper control of dNTP levels is required to prevent genomic instability. 
We will determine how ATR regulates RNR in mammalian cells. We have identified a novel substrate of Cyclin F that co-ordinates dNTP production and DNA replication. Through the study of Cyclin F-RRM2 axis we have identified novel E3s ubiquitin ligases involved in the regulation of RNR and we are currently investigating their functions. 
RNR is the target of many anti-cancer drugs (i.e. Gemcitabine, Hydroxyurea, Clodarabine, Triapine) used currently in the treatment of non-small cell lung cancer, pancreatic cancer, bladder cancer, and breast cancer. Inhibition of RNR is known to sensitise cancer cells to genotoxic stress. Identification of new pathways that regulate RNR and cell survival upon genotoxic stress might provide insight into drug resistance, predict response to chemotherapy, and prove to be a powerful tool for the design and implementation of new chemotherapies.</gtr:technicalSummary><gtr:fund><gtr:end>2017-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2005000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Role of dNTP homeostasis in cancer therapy</gtr:description><gtr:id>7231F96D-889F-404C-805C-04EE5993795D</gtr:id><gtr:impact>Manuscipt under preparation</gtr:impact><gtr:outcomeId>5464843f5e1860.54638661-1</gtr:outcomeId><gtr:partnerContribution>The collaborator has agreed to share an inhibitor under development for further testing in vitro and in vivo.</gtr:partnerContribution><gtr:piContribution>We have used an in house assay to measure dNTP levels after treating cells with an inhibitor developed by the collaborator (Thomas Helleday)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>CRUK/MRC Oxford Institute for Radiation Oncology</gtr:department><gtr:description>Role of Ribonucleotide Reductase in Hypoxia</gtr:description><gtr:id>CAEBCF19-8B50-4A97-97AD-137768DF56AC</gtr:id><gtr:impact>Manuscript in preparation</gtr:impact><gtr:outcomeId>54648995d77590.74101167-1</gtr:outcomeId><gtr:partnerContribution>They have exchanged expertise and reagents to identify the role of Ribonucleotide Reductase in hypoxia</gtr:partnerContribution><gtr:piContribution>We have exchanged expertise and reagents to identify the role of Ribonucleotide Reductase in hypoxia with the laboratory of Dr Ester Hammond</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Weatherall Institute of Molecular Medicine (WIMM)</gtr:department><gtr:description>Imaging nucleic acid metabolism in cells</gtr:description><gtr:id>049BC923-6350-43F8-A824-DC4808CFF659</gtr:id><gtr:impact>No output yet. Multi-disciplinary bridges chemistry and cell biology.</gtr:impact><gtr:outcomeId>56dd9626c77608.94715985-1</gtr:outcomeId><gtr:partnerContribution>Design novel NTPs and dNTPs analogues for imaging nucleic acid incorporation in vivo.</gtr:partnerContribution><gtr:piContribution>We will perform cell line experiment using the new NTPs and dNTPs analogues developed at the Department of Chemistry by the laboratory of Professor Tom Brown</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Mass Spectrometry Analysis of Substrates of E3 ligases involved in cancer cell survival</gtr:description><gtr:id>85FE8058-3C06-4E2D-9BF5-BF9B6023A4A7</gtr:id><gtr:impact>Manuscript in The EMBO J+ Manuscript in preparation</gtr:impact><gtr:outcomeId>5464864a10e4b8.09618804-1</gtr:outcomeId><gtr:partnerContribution>Identification of novel E3 substrates through MS analysis</gtr:partnerContribution><gtr:piContribution>Further investigation of targets identified through Mass Spectrometry</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Public engagement Talk</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>02F4855C-F522-4039-A0A2-50483B0CDA4A</gtr:id><gtr:impact>Many question regarding the impact of cancer on society and the challenge ahead were raised</gtr:impact><gtr:outcomeId>5464828e502d45.47157461</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>195455</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>H2020-MSCA-IF-2014_ST</gtr:description><gtr:end>2019-01-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:fundingRef>EU project 656872</gtr:fundingRef><gtr:id>F4A73C11-CC1F-4275-8A2C-32132BBC74A9</gtr:id><gtr:outcomeId>56dd96ffa93b51.45101258</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>An orthotropic rat model where Medulloblastoma human caner cell lines where injected in mouse cerebellum was reported in Embo J , Raducu et al., 2016</gtr:description><gtr:id>4710E46E-9702-47CC-A33A-A86F541FC281</gtr:id><gtr:impact>We provide evidences in vivo that inhibiting the E3 ligase Fbxl17 is an effective method to suppress Medulloblastoma tumour growth.</gtr:impact><gtr:outcomeId>58c6c8aae07b68.20189581</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>A new model system of Medulloblastoma</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:url>http://emboj.embopress.org/content/early/2016/05/27/embj.201593374</gtr:url></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Antibody recognising phosphorylated Sufu on S352, which is an indicator of the activation of Hedgehog signaling</gtr:description><gtr:id>A27F4741-D35F-4D7A-9E43-0512B291CF35</gtr:id><gtr:impact>Antibody recognising phosphorylated Sufu on S352, which is an indicator of the activation of Hedgehog singling. The antibody will be distributed upon request. It is being commercialised.</gtr:impact><gtr:outcomeId>58c6c92d74bbd2.54877064</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Antibody recognising phosphorylated Sufu on S352</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have analysed interacting partners of F-box proteins trough liquid chromatography/mass spectrometry analysis. We have published and deposited the list of interacting partner in a public repository (https://thebiogrid.org). Results from 3 other unrelated F-box proteins will be deposited upon publication.</gtr:description><gtr:id>5C1C8A05-E358-480B-87B1-36505D1D8F66</gtr:id><gtr:impact>Data are publicly available and researcher of other discipline can further investigate the role of the E3 ubiquitin ligase Fbxl17 in their fields.</gtr:impact><gtr:outcomeId>58c6c803bf6096.94873762</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Interacting partners and substrates of F-box proteins (E3 ubiquitin ligases)</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>https://thebiogrid.org/122315/summary/homo-sapiens/fbxl17.html</gtr:url></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0D62E58B-3F10-4114-897B-F7BD81D837F2</gtr:id><gtr:title>Two paths to let the replisome go.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f0f8a89265715face744e5e4dbb901a"><gtr:id>1f0f8a89265715face744e5e4dbb901a</gtr:id><gtr:otherNames>D'Angiolella V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>5a351697401075.86416849</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F7022ED-8E70-470B-B456-E19356C03802</gtr:id><gtr:title>Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8f446e86d6836d8e6a5da49dfe563b87"><gtr:id>8f446e86d6836d8e6a5da49dfe563b87</gtr:id><gtr:otherNames>Galluzzi L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>5aa65936d63075.60541203</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE4D6704-582D-416E-96C5-C1948E6FDC16</gtr:id><gtr:title>SCF (Fbxl17) ubiquitylation of Sufu regulates Hedgehog signaling and medulloblastoma development.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96efb3071f439435d5fdb91ba7913094"><gtr:id>96efb3071f439435d5fdb91ba7913094</gtr:id><gtr:otherNames>Raducu M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>585d3faa8cc3a5.87108630</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BFEB36A-1ECE-4832-B6F7-1D2DDD691918</gtr:id><gtr:title>FBXL13 directs the proteolysis of CEP192 to regulate centrosome homeostasis and cell migration.</gtr:title><gtr:parentPublicationTitle>EMBO reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/093b0cb52e6bd79f6355536a4aedaca4"><gtr:id>093b0cb52e6bd79f6355536a4aedaca4</gtr:id><gtr:otherNames>Fung E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1469-221X</gtr:issn><gtr:outcomeId>5aa65968624fb1.83094949</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_12007</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>